Virus Link: Novavax stock soars more than 20% after COVID-19 vaccine study shows nearly 90% efficacy in U.K., but less against new South African variant - MarketWatch

Thursday, January 28, 2021

Novavax stock soars more than 20% after COVID-19 vaccine study shows nearly 90% efficacy in U.K., but less against new South African variant - MarketWatch

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)